Im not very familiar with PTX but see a great opportunity here.
I had a go at dumbing down the data. Please correct me with any mistakes as I am not too familiar with the science or methods of testing and displaying data.
Out of 28 patients
16 were used for dosage testing
12 received recommended dosage .They also received chemo and surgery for locally advanced disease.
Of the 12, 10 were useful for recordings
5 of which had local disease the other 5 Metastic
4 of the ten were ER+ the other 6 tripple negative
Of the 5 patients with locally advanced disease which is the focus of the trial 2 had a complete response and 3 had a partial response.
It seems to work better in the case of the patient being ER+
This is positive for PTX though more testing needs to be done to rule out chemo and surgery playing a part in the results. Im not sure if these results were expected in regards to the triple negative patients.
PTX Price at posting:
12.0¢ Sentiment: Buy Disclosure: Not Held
